{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"groups":[{"description":"Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide intravenous (IV) over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.","id":"OG000","title":"Pediatric Myeloablative Conditioning"},{"description":"Patients receive fludarabine phosphate intravenous (IV) over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.","id":"OG001","title":"Adult Myeloablative Conditioning"},{"description":"Patients receive fludarabine phosphate intravenous (IV) over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.","id":"OG002","title":"Reduced-intensity Conditioning"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Participants Who Relapsed at 1 Year","type":"SECONDARY","unitOfMeasure":"participants"}